Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells

Moignic, Aline Le; Malard, Virginie; Benvegnu, Thierry; Lemiègre, Loı̈c; Berchel, Mathieu; Jaffrès, P-A; Baillou, Claude; Delost, M; Macedo, Rodney; Rochefort, Juliette; Lescaille, Géraldine; Pichon, Chantal; Lemoine, François M.; Midoux, Patrick; Mateo, Véronique

doi:10.1016/j.jconrel.2018.03.035

Cited by 96 publications

(100 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Journal of Controlled Release 303 (2019) carried cargos. In studies relevant to the in vivo characteristics, fluorescent materials are often employed as a label for tracking the behaviour of liposomes in the body [128]. However, this hardly provides a strong evidence to verify the carrier integrity, since fluorescent materials may aggregate to emit light even after carrier collapse.…”

Section: Ag Release and Liposome Integrity In Vivomentioning

confidence: 99%

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Wang

Chen

Wang

2019

Journal of Controlled Release

212

155

View full text Add to dashboard Cite

Section: Ag Release and Liposome Integrity In Vivomentioning

confidence: 99%

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Wang

Chen

Wang

2019

Journal of Controlled Release

212

155

View full text Add to dashboard Cite

“…By contrast, non‐viral vectors have no such major concerns as a result of their higher safety, especially for direct in vivo administration . In addition, they comprises more flexible tools for the loading and delivery of various types of genes, including RNA and DNA of different sizes . It is possible to rationally design novel non‐viral vectors with a high transfection efficiency and controlled gene delivery based on a deeper understanding of both physiopathological processes and gene therapy approaches.…”

Section: Discussionmentioning

confidence: 99%

“…43,44 In addition, they comprises more flexible tools for the loading and delivery of various types of genes, including RNA and DNA of different sizes. 45,46 It…”

Section: Delivery Vectorsmentioning

confidence: 99%

Clinical translation of gene medicine

Wang

Zhou

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Gene therapy has recently witnessed accelerated progress as a new therapeutic strategy with the potential to treat a range of inherited and acquired diseases. Billions of dollars have been invested in basic and clinical research on gene medicine, with ongoing clinical trials focused on cancer, monogenic diseases, cardiovascular diseases and other refractory diseases. Advances addressing the inherent challenges of gene therapy, particularly those related to retaining the delivery efficacy and minimizing unwanted immune responses, provide the basis for the widespread clinical application of gene medicine. Several types of genes delivered by viral or non‐viral delivery vectors have demonstrated encouraging results in both animals and humans. As augmented by clinical indications, gene medicine techniques have rapidly become a promising alternative to conventional therapeutic strategies because of their better clinical benefit and lower toxicities. Their application in the clinic has been extensive as a result of the approval of many gene therapy drugs in recent years. In this review, we provide a comprehensive overview of the clinical translation of gene medicine, focusing on the key events and latest progress made regarding clinical gene therapy products. We also discuss the gene types and non‐viral materials with respect to developing gene therapeutics in clinical trials.

show abstract

“…More recently, a lipid–polymer–ribonucleic acid (RNA) lipoplex (LPR) modified with a tri‐antenna of α‐ d ‐mannopyranoside (triMN‐LPR) was evaluated for efficient delivery of mRNA to DCs . Because the mannose receptors are expressed on the surface membrane of DCs and macrophages,[123b] mannose was utilized to enhance the binding affinity of the LPR to DCs.…”

Section: Application Of Polymeric Nanomedicine To Cancer Immunotherapymentioning

confidence: 99%

“…It is well‐known that cationic liposomes and polymers can protect the mRNA against RNases . Under consideration that whether positively charged lipid‐based formulations are accumulated into major organs such as liver and lungs, the triMN functionalization method would endow the synergistic effect to various types of mRNA‐based vaccines which are already known as safe vaccination strategy in some clinical trials …”

Section: Application Of Polymeric Nanomedicine To Cancer Immunotherapymentioning

confidence: 99%

Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy

Lee

Shin

Son

et al. 2019

Adv Healthcare Materials

View full text Add to dashboard Cite

Immunotherapy has emerged as a promising approach to treat cancer, since it facilitates eradication of cancer by enhancing innate and/or adaptive immunity without using cytotoxic drugs. Of the immunotherapeutic approaches, significant clinical potentials are shown in cancer vaccination, immune checkpoint therapy, and adoptive cell transfer. Nevertheless, conventional immunotherapies often involve immune‐related adverse effects, such as liver dysfunction, hypophysitis, type I diabetes, and neuropathy. In an attempt to address these issues, polymeric nanomedicines are extensively investigated in recent years. In this review, recent advances in polymeric nanomedicines for cancer immunotherapy are highlighted and thoroughly discussed in terms of 1) antigen presentation, 2) activation of antigen‐presenting cells and T cells, and 3) promotion of effector cells. Also, the future perspectives to develop ideal nanomedicines for cancer immunotherapy are provided.

show abstract

Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells

Cited by 96 publications

References 58 publications

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Clinical translation of gene medicine

Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy

Contact Info

Product

Resources

About